Cambridge Healthtech Institute's Fourth Annual Re-entering Antibacterial Discovery and Developument Summit - Short Courses
October 18-20, 2017
Omni Parker House, Boston, MA
Clinically Relevant Animal Modeling for the Evaluation of Novel Antibacterial Approaches
October 17, 2017 6:00 pm - 9:00 pm
- The course will present a progression from small animal models (Galleria, mice) to more elaborate biofilm models (mice, rats, rabbits), and conclude with larger complicated models that include trauma reflective of where these infections cause hardware and implant problems (rats, pigs, goats).
- Each instructor will present typical evaluations of antibacterial products, both successes and failures.
- Each instructor will present examples of traditional small molecule antibiotic successes/controls and compare them to alternative antibacterial treatments such as vaccines, bacteriophage, etc.
- Important considerations for model development will be addressed such as: strain selection, biofilm, method of delivery, dosing, PK/PD considerations.
- The instructors will stress why the use of various models and species are required when evaluating different antibiotics.
- Instructors will provide published examples as well as unpublished techniques, tips, and ideas.
From “White Powder” to Drug: The Path from Antibacterial Discovery to the Clinic
October 18 | 6:00-9:00 pm
This workshop will provide insight from experts in the field into the path from discovery of a compound with antibacterial activity (“white powder”, although it is often lumpy and tan) through characterization of its microbiological properties, validation of its fitness for further study and compound optimization, workups required to meet qualification as a clinical candidate, and, finally, clinical and regulatory considerations necessary for product development.
- Compound validation
- Preclinical development
- Clinical phases
- Regulatory concerns and pathways
- Partnership seeking
Technologies to Assess Permeability in Gram Negative Bacteria
October 19 | 6:00-9:00 pm
Our lack of understanding of the molecular basis for compound penetration into and efflux out of Gram-negative bacteria has been identified as a key bottleneck for the rational discovery of novel antibacterial compounds. A main driver of this knowledge gap is the historical lack of assays, tools, and/or predictive models to provide medicinal chemists with structure-activity relationships that could guide optimization of whole cell penetration (and efflux avoidance). However, there have been some recent, promising advances in the field which set the stage for future innovative approaches.
The course will cover:
- Overview of the challenging features inherent to Gram-negative cell envelopes
- Notable examples of disconnect between potent enzyme inhibition vs. whole cell activity
- Historical approaches to measuring compound uptake/accumulation
- Recent genetic and cell-based assays
- Recent label-free spectroscopic and mass spectrometry methods
- ‘Omics Approaches
- Predictive models
- Future Prospects